Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay
There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as ‘early stage.’ A 14-gene quantitative PCR-based expression...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2021-12, Vol.17 (34), p.4785-4795 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4795 |
|---|---|
| container_issue | 34 |
| container_start_page | 4785 |
| container_title | Future oncology (London, England) |
| container_volume | 17 |
| creator | Gupta, Alexander R Woodard, Gavitt A Jablons, David M Mann, Michael J Kratz, Johannes R |
| description | There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as ‘early stage.’ A 14-gene quantitative PCR-based expression profile has been extensively validated to better identify patients at high-risk of 5-year mortality after surgical resection than conventional staging – mortality that almost always results from previously undetectable metastases. Furthermore, prospective studies now suggest a predictive benefit in disease-free survival when the assay is used to guide adjuvant chemotherapy decisions in early-stage non-small-cell lung cancer patients.
There is a need for improvement in the way early-stage non-small-cell lung cancers are staged and treated because many patients with ‘early-stage’ disease suffer high rates of cancer recurrence after surgery. In recent years, a specialized test has been developed to allow better characterization of a tumor's risk of recurrence based on the genes being expressed by tumor cells. Use of this test, in conjunction with standard staging methods, is better able to identify patients at high risk of cancer recurrence after surgery. Evidence suggests that giving chemotherapy to patients at high risk of recurrence after surgery reduces recurrence rates and improves long-term patient survival. |
| doi_str_mv | 10.2217/fon-2021-0517 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9039775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564947561</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-23e59736569961003d212bfd122abf4607361357c22aa45ee830e95c14e4db6b3</originalsourceid><addsrcrecordid>eNp1UcuKFDEUDaI4Y-vSrWTpJpp3JhtBBh8DA24UlyGVutVGUkmbVAb6703T46ALV_d17rmPg9BLRt9wzszbpWTCKWeEKmYeoUtmpCRXgrLHw5fGEq2tvEDPWvtJqTRC0afoQkgp1JXRl-j7zXqo5Q5mXPoWygoN-zzjtvl9zHscM85jQFt9SiRASjj1kQ4-B6h43-M8Oqcj9ngtCUJPvmLfmj8-R08Wnxq8uLc79O3jh6_Xn8ntl0831-9vSZDCbIQLUNYIrbS1mlEqZs74tMyMcz8tUtNRY0KZMGIvFcC4DKwKTIKcJz2JHXp35j30aYU5QN6qT-5Q4-rr0RUf3b-VHH-4fblzlgprjBoEr-8JavnVoW1uje10qc9QenNcaWmlUWONHSJnaKiltQrLwxhG3UkMN8RwJzHcSYyBf_X3bg_oP98fAHsGLH3rFVqIMP7qztHoiCFm-A_5bxf7mY8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564947561</pqid></control><display><type>article</type><title>Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay</title><source>MEDLINE</source><source>PubMed Central</source><creator>Gupta, Alexander R ; Woodard, Gavitt A ; Jablons, David M ; Mann, Michael J ; Kratz, Johannes R</creator><creatorcontrib>Gupta, Alexander R ; Woodard, Gavitt A ; Jablons, David M ; Mann, Michael J ; Kratz, Johannes R</creatorcontrib><description>There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as ‘early stage.’ A 14-gene quantitative PCR-based expression profile has been extensively validated to better identify patients at high-risk of 5-year mortality after surgical resection than conventional staging – mortality that almost always results from previously undetectable metastases. Furthermore, prospective studies now suggest a predictive benefit in disease-free survival when the assay is used to guide adjuvant chemotherapy decisions in early-stage non-small-cell lung cancer patients.
There is a need for improvement in the way early-stage non-small-cell lung cancers are staged and treated because many patients with ‘early-stage’ disease suffer high rates of cancer recurrence after surgery. In recent years, a specialized test has been developed to allow better characterization of a tumor's risk of recurrence based on the genes being expressed by tumor cells. Use of this test, in conjunction with standard staging methods, is better able to identify patients at high risk of cancer recurrence after surgery. Evidence suggests that giving chemotherapy to patients at high risk of recurrence after surgery reduces recurrence rates and improves long-term patient survival.</description><identifier>ISSN: 1479-6694</identifier><identifier>ISSN: 1744-8301</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2021-0517</identifier><identifier>PMID: 34435876</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>adjuvant therapy ; Biomarkers, Tumor - genetics ; Carcinogenesis - genetics ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - therapy ; Chemotherapy, Adjuvant - statistics & numerical data ; Clinical Decision-Making ; Datasets as Topic ; Disease-Free Survival ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Lung Neoplasms - diagnosis ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Lung Neoplasms - therapy ; molecular assay ; Molecular Diagnostic Techniques - methods ; Molecular Diagnostic Techniques - statistics & numerical data ; molecular prognostic classifier ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - prevention & control ; Neoplasm Staging - methods ; non-small-cell lung cancer ; Pneumonectomy - statistics & numerical data ; predictive ; Prospective Studies ; Real-Time Polymerase Chain Reaction ; Review ; Risk Assessment - methods ; risk stratification ; tumor genetic profile</subject><ispartof>Future oncology (London, England), 2021-12, Vol.17 (34), p.4785-4795</ispartof><rights>2021 The Authors</rights><rights>2021 The Authors 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-23e59736569961003d212bfd122abf4607361357c22aa45ee830e95c14e4db6b3</citedby><cites>FETCH-LOGICAL-c437t-23e59736569961003d212bfd122abf4607361357c22aa45ee830e95c14e4db6b3</cites><orcidid>0000-0002-2813-6175</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039775/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039775/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34435876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Alexander R</creatorcontrib><creatorcontrib>Woodard, Gavitt A</creatorcontrib><creatorcontrib>Jablons, David M</creatorcontrib><creatorcontrib>Mann, Michael J</creatorcontrib><creatorcontrib>Kratz, Johannes R</creatorcontrib><title>Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as ‘early stage.’ A 14-gene quantitative PCR-based expression profile has been extensively validated to better identify patients at high-risk of 5-year mortality after surgical resection than conventional staging – mortality that almost always results from previously undetectable metastases. Furthermore, prospective studies now suggest a predictive benefit in disease-free survival when the assay is used to guide adjuvant chemotherapy decisions in early-stage non-small-cell lung cancer patients.
There is a need for improvement in the way early-stage non-small-cell lung cancers are staged and treated because many patients with ‘early-stage’ disease suffer high rates of cancer recurrence after surgery. In recent years, a specialized test has been developed to allow better characterization of a tumor's risk of recurrence based on the genes being expressed by tumor cells. Use of this test, in conjunction with standard staging methods, is better able to identify patients at high risk of cancer recurrence after surgery. Evidence suggests that giving chemotherapy to patients at high risk of recurrence after surgery reduces recurrence rates and improves long-term patient survival.</description><subject>adjuvant therapy</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Carcinogenesis - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Chemotherapy, Adjuvant - statistics & numerical data</subject><subject>Clinical Decision-Making</subject><subject>Datasets as Topic</subject><subject>Disease-Free Survival</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - therapy</subject><subject>molecular assay</subject><subject>Molecular Diagnostic Techniques - methods</subject><subject>Molecular Diagnostic Techniques - statistics & numerical data</subject><subject>molecular prognostic classifier</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Neoplasm Staging - methods</subject><subject>non-small-cell lung cancer</subject><subject>Pneumonectomy - statistics & numerical data</subject><subject>predictive</subject><subject>Prospective Studies</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Review</subject><subject>Risk Assessment - methods</subject><subject>risk stratification</subject><subject>tumor genetic profile</subject><issn>1479-6694</issn><issn>1744-8301</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UcuKFDEUDaI4Y-vSrWTpJpp3JhtBBh8DA24UlyGVutVGUkmbVAb6703T46ALV_d17rmPg9BLRt9wzszbpWTCKWeEKmYeoUtmpCRXgrLHw5fGEq2tvEDPWvtJqTRC0afoQkgp1JXRl-j7zXqo5Q5mXPoWygoN-zzjtvl9zHscM85jQFt9SiRASjj1kQ4-B6h43-M8Oqcj9ngtCUJPvmLfmj8-R08Wnxq8uLc79O3jh6_Xn8ntl0831-9vSZDCbIQLUNYIrbS1mlEqZs74tMyMcz8tUtNRY0KZMGIvFcC4DKwKTIKcJz2JHXp35j30aYU5QN6qT-5Q4-rr0RUf3b-VHH-4fblzlgprjBoEr-8JavnVoW1uje10qc9QenNcaWmlUWONHSJnaKiltQrLwxhG3UkMN8RwJzHcSYyBf_X3bg_oP98fAHsGLH3rFVqIMP7qztHoiCFm-A_5bxf7mY8</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Gupta, Alexander R</creator><creator>Woodard, Gavitt A</creator><creator>Jablons, David M</creator><creator>Mann, Michael J</creator><creator>Kratz, Johannes R</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2813-6175</orcidid></search><sort><creationdate>20211201</creationdate><title>Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay</title><author>Gupta, Alexander R ; Woodard, Gavitt A ; Jablons, David M ; Mann, Michael J ; Kratz, Johannes R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-23e59736569961003d212bfd122abf4607361357c22aa45ee830e95c14e4db6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adjuvant therapy</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Carcinogenesis - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Chemotherapy, Adjuvant - statistics & numerical data</topic><topic>Clinical Decision-Making</topic><topic>Datasets as Topic</topic><topic>Disease-Free Survival</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - therapy</topic><topic>molecular assay</topic><topic>Molecular Diagnostic Techniques - methods</topic><topic>Molecular Diagnostic Techniques - statistics & numerical data</topic><topic>molecular prognostic classifier</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Neoplasm Staging - methods</topic><topic>non-small-cell lung cancer</topic><topic>Pneumonectomy - statistics & numerical data</topic><topic>predictive</topic><topic>Prospective Studies</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Review</topic><topic>Risk Assessment - methods</topic><topic>risk stratification</topic><topic>tumor genetic profile</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Alexander R</creatorcontrib><creatorcontrib>Woodard, Gavitt A</creatorcontrib><creatorcontrib>Jablons, David M</creatorcontrib><creatorcontrib>Mann, Michael J</creatorcontrib><creatorcontrib>Kratz, Johannes R</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Alexander R</au><au>Woodard, Gavitt A</au><au>Jablons, David M</au><au>Mann, Michael J</au><au>Kratz, Johannes R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>17</volume><issue>34</issue><spage>4785</spage><epage>4795</epage><pages>4785-4795</pages><issn>1479-6694</issn><issn>1744-8301</issn><eissn>1744-8301</eissn><abstract>There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as ‘early stage.’ A 14-gene quantitative PCR-based expression profile has been extensively validated to better identify patients at high-risk of 5-year mortality after surgical resection than conventional staging – mortality that almost always results from previously undetectable metastases. Furthermore, prospective studies now suggest a predictive benefit in disease-free survival when the assay is used to guide adjuvant chemotherapy decisions in early-stage non-small-cell lung cancer patients.
There is a need for improvement in the way early-stage non-small-cell lung cancers are staged and treated because many patients with ‘early-stage’ disease suffer high rates of cancer recurrence after surgery. In recent years, a specialized test has been developed to allow better characterization of a tumor's risk of recurrence based on the genes being expressed by tumor cells. Use of this test, in conjunction with standard staging methods, is better able to identify patients at high risk of cancer recurrence after surgery. Evidence suggests that giving chemotherapy to patients at high risk of recurrence after surgery reduces recurrence rates and improves long-term patient survival.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>34435876</pmid><doi>10.2217/fon-2021-0517</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2813-6175</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2021-12, Vol.17 (34), p.4785-4795 |
| issn | 1479-6694 1744-8301 1744-8301 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9039775 |
| source | MEDLINE; PubMed Central |
| subjects | adjuvant therapy Biomarkers, Tumor - genetics Carcinogenesis - genetics Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - therapy Chemotherapy, Adjuvant - statistics & numerical data Clinical Decision-Making Datasets as Topic Disease-Free Survival Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Lung Neoplasms - diagnosis Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - therapy molecular assay Molecular Diagnostic Techniques - methods Molecular Diagnostic Techniques - statistics & numerical data molecular prognostic classifier Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - prevention & control Neoplasm Staging - methods non-small-cell lung cancer Pneumonectomy - statistics & numerical data predictive Prospective Studies Real-Time Polymerase Chain Reaction Review Risk Assessment - methods risk stratification tumor genetic profile |
| title | Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T09%3A22%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20outcomes%20and%20staging%20in%20non-small-cell%20lung%20cancer%20guided%20by%20a%20molecular%20assay&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Gupta,%20Alexander%20R&rft.date=2021-12-01&rft.volume=17&rft.issue=34&rft.spage=4785&rft.epage=4795&rft.pages=4785-4795&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2021-0517&rft_dat=%3Cproquest_pubme%3E2564947561%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564947561&rft_id=info:pmid/34435876&rfr_iscdi=true |